Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRA platform study of novel combination therapies in advanced or metastatic non-small cell lung cancer
CTR20252768Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rilvegostomig, ramucirumab, datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Aug 2025; status: active.
02
Drugs
rilvegostomigramucirumabdatopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252768.